Fate Therapeutics (FATE) Long-Term Debt Issuances (2013 - 2014)
Fate Therapeutics (FATE) posted Long-Term Debt Issuances of $10.0 million for Q4 2014, down 51.77% on a QoQ basis from $20.7 million in Q3 2013.
Fate Therapeutics (FATE) Long-Term Debt Issuances (2013 - 2014) Analysis & Trends
Fate Therapeutics' Long-Term Debt Issuances history runs 2 years deep, the most recent figure standing at $10.0 million for Q4 2014.
- Quarterly Long-Term Debt Issuances changed N/A year-over-year to $10.0 million in Q4 2014, while the trailing twelve-month figure through Dec 2017 was $10.0 million (changed N/A YoY) and the FY2017 annual result came in at $15.0 million, up 50.0% from the prior year.
- Long-Term Debt Issuances was $10.0 million for Q4 2014 at Fate Therapeutics, down from $20.7 million in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $20.7 million in Q3 2013 and bottomed at $10.0 million in Q4 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Fate Therapeutics | 302.48 Mn | 302.48 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2014 | 10.00 Mn |
| Dec 31, 2014 | 10.00 Mn |
| Sep 30, 2013 | 20.74 Mn |
| Sep 30, 2013 | 20.74 Mn |